AveXis Inc (NASDAQ:AVXS)‘s stock had its “buy” rating restated by analysts at Chardan Capital in a note issued to investors on Friday. They currently have a $100.00 target price on the stock. Chardan Capital’s target price would indicate a potential upside of 25.39% from the stock’s previous close.

Several other analysts have also commented on the stock. Jefferies Group LLC increased their target price on shares of AveXis from $79.00 to $92.00 and gave the company a “buy” rating in a research note on Friday. Goldman Sachs Group Inc increased their target price on shares of AveXis from $91.00 to $108.00 and gave the company a “buy” rating in a research note on Friday. BMO Capital Markets reissued an “outperform” rating and set a $95.00 target price (up from $85.00) on shares of AveXis in a research note on Friday. Finally, Zacks Investment Research raised shares of AveXis from a “sell” rating to a “hold” rating in a research note on Tuesday, February 14th. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. AveXis currently has a consensus rating of “Buy” and an average price target of $85.33.

Analyst Recommendations for AveXis (NASDAQ:AVXS)

Shares of AveXis (NASDAQ:AVXS) opened at 79.75 on Friday. The stock’s market capitalization is $2.21 billion. The stock’s 50 day moving average is $62.69 and its 200 day moving average is $53.26. AveXis has a 52 week low of $20.51 and a 52 week high of $85.98.

AveXis (NASDAQ:AVXS) last released its earnings results on Thursday, March 16th. The company reported ($0.92) EPS for the quarter, missing the consensus estimate of ($0.80) by $0.12. During the same quarter last year, the business earned ($1.82) EPS. Analysts anticipate that AveXis will post ($3.93) EPS for the current fiscal year.

Your IP Address:

Hedge funds have recently added to or reduced their stakes in the stock. Norges Bank purchased a new stake in shares of AveXis during the fourth quarter valued at approximately $1,193,000. RTW Investments LP increased its stake in shares of AveXis by 2.8% in the fourth quarter. RTW Investments LP now owns 849,043 shares of the company’s stock valued at $40,525,000 after buying an additional 23,063 shares during the period. Boxer Capital LLC increased its stake in shares of AveXis by 243.2% in the fourth quarter. Boxer Capital LLC now owns 1,028,763 shares of the company’s stock valued at $49,103,000 after buying an additional 729,007 shares during the period. Perceptive Advisors LLC purchased a new stake in shares of AveXis during the fourth quarter valued at approximately $22,602,000. Finally, Franklin Resources Inc. increased its stake in shares of AveXis by 5.8% in the fourth quarter. Franklin Resources Inc. now owns 1,196,960 shares of the company’s stock valued at $57,131,000 after buying an additional 65,550 shares during the period. 68.31% of the stock is owned by institutional investors and hedge funds.

AveXis Company Profile

AveXis, Inc, formerly Biolife Cell Bank, Inc, is a clinical-stage gene therapy company. The Company operates through developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.

5 Day Chart for NASDAQ:AVXS

Receive News & Stock Ratings for AveXis Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis Inc and related stocks with our FREE daily email newsletter.